Ophthalmic nano-drug delivery system loaded with cyclosporine as well as preparation method and application of ophthalmic nano-drug delivery system
The nano micelle technology loading cyclosporine has solved the problems of low solubility and high irritation in existing eye drops, and the stable existence and rapid effect of high concentrations of cyclosporine is achieved, improving patient tolerance and production safety sex.
Patent Information
- Application Number
- CN202410967615.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-24
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
The existing cyclosporine eye drops have problems such as low solubility, insufficient concentration and high local irritation, which are difficult to meet the needs of high concentration, safe and effective treatment.
Using nano micelle technology, using specific amphiphilic polymers to form micelle particles and load cyclosporine, a high concentration of cyclosporine ophthalmic nanodrug delivery system is prepared through direct hydration method, avoiding the use of organic solvents, and improving the drug in the eye concentration accumulation and stability of the part.
It has achieved stable presence of high concentrations of cyclosporine in aqueous solution, reducing local irritation, improving the speed of drug development and patient compliance, and the process is safe and environmentally friendly, suitable for industrial production.
Smart Images

Figure CN118903005A_ABST
Abstract
Description
[0001] This application claims the priority of a Chinese patent application with an application date of November 24, 2023, application number 202311583807.8, and invention name “A cyclosporine-loaded ocular nanodrug delivery system, preparation method and application thereof”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The invention belongs to the technical field of biomedicine and relates to an ophthalmic nano drug delivery system loaded with cyclosporine and a preparation method and application thereof. Background Art
[0003] Cyclosporine, also known as cyclosporin A, is a potent and selective immunosuppressant isolated from soil mold. In recent years, cyclosporine has been used to treat dry eye (keratoconjunctivitis sicca) and keratoconjunctivitis. Its mechanism of action includes inhibiting T cell activation, thereby reducing the production of inflammatory cytokines, resisting cell apoptosis, increasing goblet cell density and mucin secretion levels, and increasing tear flow. Cyclosporine is safe and effective as a long-term clinical medication, has no systemic adverse reactions, and can significantly improve the discomfort symptoms of dry eye, keratoconjunctivitis and related eye diseases.
[0004] Cyclosporine is a cyclic polypeptide composed of 11 amino acids. It is a highly lipid-soluble drug with a water solubility of only 12 ng / mL (25°C). Therefore, it is necessary to improve its solubility when preparing it into eye drops. At present, there are many preparations of cyclosporine on the market, including cyclosporine 0.05% emulsion (Restasis), 0.1% emulsion, 0.05% cyclosporine eye drops of Shenyang Xingqi Eye Medicine Co., Ltd., etc. Preparations with oil as solvent usually have many disadvantages, especially for local use in the eye, there is a strong burning sensation and irritation. Moreover, the concentration of cyclosporine is too low, and it is difficult to reach the effective therapeutic concentration of the drug. Therefore, it is urgent to develop new safe, effective and stable high-concentration cyclosporine eye drops. Summary of the invention
[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide an innovative ophthalmic nano drug delivery system loaded with cyclosporine and its preparation method and application, and specifically to a cyclosporine-loaded ophthalmic nano drug delivery system and its preparation method and a cyclosporine eye drop and its preparation method. The present invention uses nano micelle technology to prepare a high-concentration stable ophthalmic solution preparation of cyclosporine, a poorly soluble drug. The preparation does not contain any oil phase components, has low irritation, and does not use any organic solvents in the preparation process, so it is highly safe.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides an ophthalmic nano drug delivery system loaded with cyclosporine, wherein the nano drug delivery system comprises, by weight, 0.1-10 parts of an amphiphilic polymer forming micelle particles and 0.01-1 parts of cyclosporine loaded in the micelle particles.
[0008] The specific point values that can be selected from the 0.1-10 parts include but are not limited to 0.1 parts, 0.3 parts, 0.5 parts, 0.8 parts, 1 part, 1.2 parts, 1.5 parts, 1.8 parts, 2 parts, 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.5 parts, 4 parts, 4.3 parts, 4.5 parts, 4.8 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, etc.; the specific point values that can be selected from the 0.01-1 part include but are not limited to 0.01 parts, 0.03 parts, 0.05 parts, 0.08 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, etc.
[0009] The ophthalmic nano drug delivery system of the present invention selects the following specific polymer types, and solves the solubility problem of cyclosporine in water by means of nano micelle technology, so that cyclosporine can be stably present in the aqueous solution at a higher concentration, which is conducive to the accumulation of higher concentrations of the drug in the eye tissue, thereby facilitating the drug to take effect faster. In addition, the local irritation is low, which can improve the compliance and tolerance of patients.
[0010] Preferably, the amphiphilic polymer is selected from any one or a combination of at least two of the following structural compounds:
[0011]
[0012] In the above structural compound, R is independently selected from C9-C26 alkyl; R1 is selected from C1-C5 alkylene; R2 is independently selected from H, methyl, ethyl; M+ is selected from Na + , K + or NH4 + ; The molecular weight of the polyethylene glycol chain segments is independently 500-20000.
[0013] The C9-C26 alkyl group refers to C9 alkyl, C10 alkyl, C11 alkyl, C12 alkyl, C13 alkyl, C14 alkyl, C15 alkyl, C16 alkyl, C17 alkyl, C18 alkyl, C19 alkyl, C20 alkyl, C21 alkyl, C22 alkyl, C23 alkyl, C24 alkyl, C25 alkyl, C26 alkyl. The C1-C5 alkylene group refers to C1 alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene.
[0014] The molecular weight of the polyethylene glycol chain segment can be independently selected to be 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 10000, 13000, 15000, 20000, etc. Other specific points within this numerical range can be selected and will not be described in detail here.
[0015] The cyclosporine involved in the present invention can not be loaded by any amphiphilic polymer to form a stable micelle system, but can only be realized under the above-mentioned polymer type with a specific structure, especially the following preferred polymer type. Different from the thin film hydration method and other methods, under this condition, the direct hydration method can achieve high-load and high-stability entrapment of cyclosporine without using any organic solvent, which is conducive to industrialized scale-up production and is safe and environmentally friendly.
[0016] Preferably, the amphiphilic polymer is selected from any one or a combination of at least two of the following compounds: TPGS (vitamin E polyethylene glycol succinate), mPEG-DSPE (methoxy-polyethylene glycol-phosphatidylethanolamine), mPEG-DPPE (methoxy-polyethylene glycol-dipalmitoylphosphatidylethanolamine), ALC-0159 (methoxy polyethylene glycol ditetradecyl acetamide), mPEG-DMG (1,2-dimyristoyl-rac-glycerol-3-methyl The molecular weight of the polyethylene glycol segments in the above compounds is independently 500-20000, for example 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 10000, 13000, 15000, 20000, etc. Other specific point values within the numerical range can be selected, which will not be described one by one here.
[0017] Preferably, the particle size of the nano drug delivery system is 5-100 nm, for example 5 nm, 10 nm, 15 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, etc. Other specific point values within this numerical range can be selected and will not be described here one by one.
[0018] In a second aspect, the present invention provides a method for preparing the cyclosporine-loaded ophthalmic nanodrug delivery system according to the first aspect, the preparation method comprising: mixing and dissolving cyclosporine with an aqueous solution of an amphiphilic polymer to obtain the cyclosporine-loaded ophthalmic nanodrug delivery system.
[0019] The ophthalmic nano drug delivery system loaded with cyclosporine of the present invention is prepared by direct hydration method, which is different from the thin film hydration method and other methods for preparing most polymer micelles. This method does not use any organic solvent, is conducive to industrialized scale-up production, and is safe and environmentally friendly. In addition, the ophthalmic nano drug system loaded with cyclosporine is very stable, has a long shelf life, and is conducive to storage and transportation.
[0020] In a third aspect, the present invention provides use of the cyclosporine-loaded ophthalmic nanodrug delivery system according to the first aspect in the preparation of an ophthalmic cyclosporine preparation.
[0021] In a fourth aspect, the present invention provides a cyclosporine eye drop, wherein the raw materials for preparing the cyclosporine eye drop include the ophthalmic nanodrug delivery system loaded with cyclosporine as described in the first aspect.
[0022] Preferably, the raw materials for preparing the cyclosporine eye drops further include any one of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative, or a combination of at least two of them.
[0023] Preferably, the mass percentage of cyclosporine in the cyclosporine eye drops is not less than 0.05%, for example 0.05%, 0.06%, 0.07%, 0.08%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc. Other specific point values within this numerical range can be selected, which will not be repeated here.
[0024] In a fifth aspect, the present invention provides a method for preparing the cyclosporine eye drops according to the fourth aspect, the preparation method comprising:
[0025] Any one or a combination of at least two of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative are mixed with cyclosporine and an amphiphilic polymer and dissolved in water, and water is added to adjust the total volume so that the cyclosporine reaches the target concentration.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] The present invention solves the solubility problem of cyclosporine in water by means of an innovative carrier system, and can prepare a high-concentration cyclosporine micelle solution, which is conducive to the accumulation of a higher concentration of the drug in the ocular tissue, thereby facilitating the drug to take effect faster; and the local irritation is low, which can improve the compliance and tolerance of patients; the micelle solution has good stability, which is conducive to storage and transportation. And the ocular nano drug delivery system is prepared by a direct hydration method, which is different from the thin film hydration method for preparing most polymer micelles, etc. This method does not use any organic solvent, is conducive to industrialized scale-up production, and is safe and environmentally friendly. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 is a graph showing the change of cyclosporine concentration in the cornea over time after use of the product of the present invention and the control product;
[0029] Figure 2 is a graph showing the change of cyclosporine concentration in the bulbar conjunctiva over time after use of the product of the present invention and the control product;
[0030] Figure 3 is a graph showing the change in cyclosporine concentration over time in the upper and lower eyelids after using the product of the present invention and the control product;
[0031] Figure 4 This is a graph showing the change in cyclosporine concentration in the sclera over time after use of the product of the present invention and the control product. DETAILED DESCRIPTION
[0032] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
[0033] The cyclosporine involved in the following content was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; vitamin E polyethylene glycol succinate (TPGS for short, molecular weight 1513, of which the molecular weight of the PEG segment is about 1000) was purchased from Shanghai Lianlu Industrial Co., Ltd.; mPEG-2000-DSPE was purchased from Jiangsu Southeast Nano Co., Ltd.; mPEG5000-DPPE was purchased from Aladdin Reagent (Shanghai) Co., Ltd.; ALC-0159 was purchased from Meiluo Technology Co., Ltd.; mPEG2000-DMG was purchased from MedChemExpress; mPEG2000-DSG was purchased from MedChemExpress; and hydroxypropyl methylcellulose (labeled viscosity 4000) was purchased from Tai'an Ruitai Cellulose Co., Ltd.
[0034] The instruments used in the following contents include: laser particle size analyzer (Malvern, zetasizer ZSP); high performance liquid chromatograph (Shimadzu LC-20-AT); high performance liquid chromatography-mass spectrometry (Shimadzu LCMS8050); other reagents or instruments not specified are conventional products that can be purchased commercially.
[0035] The cyclosporine content was measured by the external standard method. The sample was centrifuged to obtain the supernatant before detection. The conditions for high performance liquid chromatography detection were: Agilent Zorbax C18 column, 5 μm, 4.6×250 mm, flow rate 1.0 mL / min, column temperature 70° C., detection wavelength 210 nm, injection volume 20 μL. The mobile phase was water: acetonitrile: tert-butyl methyl ether: phosphoric acid solution (85%) = 1040: 860: 100: 2 (volume ratio), isocratic elution.
[0036] Example 1
[0037] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0038] Place 8.6 mL of pure water in a flask and continue stirring at 25°C. Add 430 mg of TPGS and allow it to gradually dissolve. Take 3 mL of the solution and add 12 mL of pure water to obtain a 1% TPGS solution. Add 10 mg of cyclosporine to 5 mL of the solution, raise the solution temperature to 60°C, continue stirring until the cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles to obtain the product.
[0039] Example 2
[0040] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0041] Place 14 mL of pure water in a flask and continue stirring at 25°C. Add 200 mg of mPEG-2000-DSPE and allow it to gradually dissolve. Add 20 mg of cyclosporine to the solution, raise the solution temperature to 60°C, continue stirring until cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles to obtain the product.
[0042] Example 3
[0043] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0044] Place 64 mL of pure water in a flask and continue stirring at 25°C. Add 894 mg of mPEG-2000-DSPE and allow it to gradually dissolve. Take 13.7 mL of the solution, add 28 mg of cyclosporine, raise the solution temperature to 60°C, continue stirring until cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles to obtain the product.
[0045] Example 4
[0046] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0047] Place 3.6 mL of pure water in a flask and continue stirring at 25°C. Add 50 mg of mPEG-5000-DPPE and allow it to gradually dissolve. Add 5 mg of cyclosporine, raise the temperature of the solution to 60°C, continue stirring until the cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles.
[0048] Example 5
[0049] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0050] Place 3.6 mL of pure water in a flask and continue stirring at 25°C. Add 50 mg of ALC-0159 and allow it to gradually dissolve. Add 5 mg of cyclosporine, raise the solution temperature to 60°C, continue stirring until cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles.
[0051] Example 6
[0052] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0053] Place 3.6 mL of pure water in a flask and continue stirring at 25°C. Add 50 mg of mPEG 2000-DSPE and allow it to gradually dissolve. Add 10 mg of cyclosporine, raise the temperature of the solution to 60°C, continue stirring until the cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles to obtain the product.
[0054] Example 7
[0055] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0056] Place 3.6 mL of pure water in a flask and continue stirring at 25°C. Add 50 mg of mPEG 2000-DMG and allow it to gradually dissolve. Add 5 mg of cyclosporine, raise the solution temperature to 60°C, continue stirring until cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles.
[0057] Example 8
[0058] This embodiment provides an ophthalmic nano drug delivery system loaded with cyclosporine, and the preparation method is as follows:
[0059] Place 3.6 mL of pure water in a flask and continue stirring at 25°C. Add 50 mg of mPEG 2000-DSG and allow it to gradually dissolve. Add 5 mg of cyclosporine, raise the temperature of the solution to 60°C, continue stirring until the cyclosporine is dissolved, and filter the solution through a 0.22 micron filter to remove insoluble particles.
[0060] Comparative Example 1
[0061] The preparation method of this comparative example differs from that of Example 1 only in that TPGS is replaced with polyoxyethylene castor oil 40 (a product purchased from BASF) of equal mass, and other process operations remain unchanged. The results show that cyclosporine cannot be dissolved after being added, and drug precipitation occurs, and micelles cannot be formed.
[0062] Comparative Example 2
[0063] The preparation method of this comparative example differs from that of Example 1 only in that TPGS is replaced with poloxamer 407 of equal mass, and other process operations remain unchanged. The results show that after 10 hours, the solution is still turbid, cyclosporine fails to dissolve, and nanomicelles cannot be formed.
[0064] Comparative Example 3
[0065] The preparation method of this comparative example differs from that of Example 1 only in that TPGS is replaced with poloxamer 188 of equal mass, and other process operations remain unchanged. The results show that after 10 hours, the solution is still turbid, cyclosporine fails to dissolve, and nanomicelles cannot be formed.
[0066] Comparative Example 4
[0067] The preparation method of this comparative example is different from that of Example 1 only in that TPGS is replaced with polyethylene glycol-15 hydroxystearate (a product purchased from BASF) of equal mass, and other process operations remain unchanged. The results show that cyclosporine can be dissolved to form a colorless, clear and transparent solution. The solution will produce a large amount of precipitation after being placed at 25°C and 40°C for 18 hours respectively, and stable nano-micelles cannot be formed.
[0068] Comparative Example 5
[0069] The preparation method of this comparative example is different from that of Example 1 only in that TPGS is replaced with an equal mass of mPEG2000-PLGA (Mn 4500) (purchased from Sigma Aldrich). The results show that the auxiliary material cannot be completely dissolved in water at 25°C.
[0070] Comparative Example 6
[0071] The preparation method of this comparative example is different from that of Example 1 only in that TPGS is replaced by an equal amount of mPEG750-PLA (Mn 1000) (a product purchased from Sigma Aldrich). The results show that the auxiliary material cannot be completely dissolved in water at 25°C.
[0072] Test Example 1
[0073] In this test example, the products obtained in Examples 1 to 8 were characterized by particle size using a laser particle size analyzer. The results are shown in Table 1.
[0074] Table 1
[0075] Group Characteristics Particle size PDI Example 1 Colorless, clear and transparent 17.45nm 0.176 Example 2 Colorless, clear and transparent 20.15nm 0.247 Example 3 Colorless, clear and transparent 31.19nm 0.155 Example 4 Colorless, clear and transparent 33.68nm 0.458 Example 5 Colorless, clear and transparent 17.22nm 0.287 Example 6 Colorless, clear and transparent 31.21nm 0.322 Example 7 Colorless, clear and transparent 20.25nm 0.307 Example 8 Colorless, clear and transparent 20.20nm 0.265
[0076] It can be seen from the data in Table 1 that the ophthalmic nano drug delivery system loaded with cyclosporine according to the present invention can be prepared by using a direct hydration method, and the system is colorless, clear and transparent with uniform particle size.
[0077] Test Example 2
[0078] In this test example, the products obtained in Examples 1-8 were placed at 35° C. for 30 days and then characterized by particle size using a laser particle size analyzer. The results are shown in Table 2.
[0079] Table 2
[0080] Group Characteristics Particle size PDI Example 1 Colorless, clear and transparent 18.97nm 0.181 Example 2 Colorless, clear and transparent 28.42nm 0.174 Example 3 Colorless, clear and transparent 27.56nm 0.249 Example 4 Colorless, clear and transparent 36.52nm 0.238 Example 5 Colorless, clear and transparent 18.36nm 0.249 Example 6 Colorless, clear and transparent 32.53nm 0.141 Example 7 Colorless, clear and transparent 21.82nm 0.203 Example 8 Colorless, clear and transparent 18.75nm 0.259
[0081] It can be seen from the data in Table 2 that the cyclosporine-loaded ophthalmic nano drug delivery system of the present invention has a uniform particle size after being placed at 35° C. for 30 days, without significant changes, and has good stability.
[0082] Application Example 1
[0083] Dissolve 530 mg of disodium hydrogen phosphate (dihydrate), 470 mg of sodium dihydrogen phosphate (anhydrous), and 50 mg of sodium chloride in 10 mL of pure water, and take 1 mL for later use; dissolve 300 mg of thickener hydroxypropyl methylcellulose in 50 mL of pure water, and take 1 mL for later use; take 7 mL of the product of Example 2 and mix evenly with the above two solutions, and add pure water to make the final volume 10 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.
[0084] Application Example 2
[0085] Dissolve 795 mg of disodium hydrogen phosphate (dihydrate), 705 mg of sodium dihydrogen phosphate (anhydrous), and 75 mg of sodium chloride in 15 mL of pure water, and take 2.8 mL for later use; dissolve 173 mg of thickener hydroxypropyl methylcellulose in 20 mL of pure water, and take 3.3 mL for later use; take 13.7 mL of the product of Example 3 and mix it evenly with the above two solutions, and add pure water to make the final volume 27.7 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.
[0086] Application Example 3
[0087] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 0.5 mL for later use; dissolve 100 mg of thickener hydroxypropyl methylcellulose in 15 mL of pure water, and take 0.8 mL for later use; take 3.6 mL of the product of Example 4 and mix evenly with the above two solutions, and add pure water to make the final volume 5 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.
[0088] Application Example 4
[0089] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 0.5 mL for later use; dissolve 100 mg of thickener hydroxypropyl methylcellulose in 15 mL of pure water, and take 0.8 mL for later use; take 3.6 mL of the product of Example 5 and mix evenly with the above two solutions, and add pure water to make the final volume 5 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.
[0090] Application Example 5
[0091] Dissolve 96 mg of disodium hydrogen phosphate (dihydrate), 105 mg of sodium dihydrogen phosphate (anhydrous), and 95 mg of sodium chloride in 2 mL of pure water, and take 0.5 mL for later use; dissolve 100 mg of thickener hydroxypropyl methylcellulose in 15 mL of pure water, and take 0.8 mL for later use; take 3.6 mL of the product of Example 6 and mix evenly with the above two solutions, and add pure water to make the final volume 5 mL. Filter the solution through a 0.22 micron filter to remove insoluble particles.
[0092] Test Example 3
[0093] In this test example, the products obtained in Example 1 and Application Examples 1-5 were placed at 35° C. for 30 days, and the cyclosporine content was measured before and after the placement using a high performance liquid chromatograph. The results are shown in Table 3.
[0094] Table 3
[0095] Group before placing After placement Example 1 0.0806% 0.0804% Application Example 1 0.0990% 0.0980% Application Example 2 0.0950% 0.0981% Application Example 3 0.0896% 0.0873% Application Example 4 0.0995% 0.0997% Application Example 5 0.1988% 0.1846%
[0096] It can be seen from the data in Table 3 that the cyclosporine-loaded ophthalmic nano drug delivery system of the present invention has no significant change in the content of cyclosporine after being placed at 35° C. for 30 days, and has good stability.
[0097] Test Example 4
[0098] This test example is used to conduct eye irritation test on the products prepared using Examples 1-5:
[0099] A total of 15 healthy rabbits were randomly divided into 5 groups, 3 rabbits in each group. 50 μL of the test product was dripped into the left eye of each rabbit, and 50 μL of normal saline was dripped into the right eye. The eyelids were gently closed for 10 seconds. The drug was administered 4 times a day for 7 consecutive days. The local reactions of the cornea, iris, and conjunctiva of the rabbits were observed before administration and 1, 2, 4, 24, 48, and 72 hours after the last administration every day, and the total score was calculated. The irritation score of normal saline was 0 points. Test scoring criteria and methods: See the table below.
[0100]
[0101]
[0102] The result judgment criteria are shown in the following table:
[0103] Thrill Level Total score Criteria 1 0-3 points Non-irritating 2 4-8 points Mild irritation 3 9-12 points Moderate irritation 4 13-16 points Intensity of stimulation
[0104] The eye irritation test results of each group are shown in Table 4:
[0105] Table 4
[0106] Group 1h 2h 4h 24h 48h 72h Application Example 1 0 0 0 0 0 0 Application Example 2 0 0 0 0 0 0 Application Example 3 0 0 0 0 0 0 Application Example 4 0 0 0 0 0 0 Application Example 5 0 0 0 0 0 0
[0107] It can be seen from the data in Table 4 that the ophthalmic nano drug delivery system loaded with cyclosporine of the present invention has no obvious irritation to the rabbit eyes and is safe and mild.
[0108] Test Example 5
[0109] This test case performs a pharmacokinetic test on the product prepared in Example 2:
[0110] A total of 60 healthy rabbits were randomly divided into 20 groups, with 3 rabbits in each group. 10 groups of experimental rabbits were dripped with 35 μL of the product prepared in Application Example 2 in both eyes, and the other 10 groups of experimental rabbits were dripped with a control product (0.05% cyclosporine eye drops II produced by Shenyang Xingqi Eye Medicine Co., Ltd.) )35μL. The experimental rabbits in groups 1-10 were killed at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 hours after administration, and the upper and lower eyelids and conjunctiva were removed. Immediately afterwards, the rabbits were enucleated, and the eyeballs were dissected to separate the cornea and sclera. After grinding and homogenizing each tissue, the cyclosporine content in the tissue was analyzed using a high-performance liquid chromatography-mass spectrometer. Pharmacokinetic parameters of cyclosporine in the cornea, conjunctiva, upper and lower eyelids, and sclera C max and AUC (0-t) See Table 5. Changes of cyclosporine drug concentrations in the cornea, conjunctiva, upper and lower eyelids, and sclera over time are shown in Figure 1-Figure 4 In the figure, the X-axis is time (h) and the Y-axis is the cyclosporine drug concentration in the tissue (ng / g).
[0111] Table 5
[0112]
[0113] From Table 5 and Figure 1-Figure 4 The data show that the ocular nano drug delivery system loaded with cyclosporine involved in the present invention significantly increased the concentration and exposure of cyclosporine in four ocular tissues (AUC (0-t) ), indicating that it may produce better results in actual clinical use.
[0114] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0115] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0116] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A cyclosporine-loaded ophthalmic nanodrug delivery system, characterized in that: The nano drug delivery system comprises, by weight, 0.1-10 parts of an amphiphilic polymer forming micelle particles and 0.01-1 parts of cyclosporine loaded in the micelle particles.
2. The ophthalmic nano drug delivery system loaded with cyclosporine according to claim 1, characterized in that: The amphiphilic polymer is selected from any one or a combination of at least two of the following structural compounds: In the above structural compound, R is independently selected from C9-C26 alkyl; R1 is selected from C1-C5 alkylene; R2 is independently selected from H, methyl, ethyl; M+ is selected from Na + , K + or NH4 + ; The molecular weight of the polyethylene glycol chain segments is independently 500-20000.
3. The ophthalmic nano drug delivery system loaded with cyclosporine according to claim 1 or 2, characterized in that: The amphiphilic polymer is selected from any one or a combination of at least two of the following compounds: TPGS, mPEG-DSPE, mPEG-DPPE, ALC-0159, mPEG-DMG, and mPEG-DSG; wherein the molecular weight of the polyethylene glycol segments is independently 500-20000.
4. The ophthalmic nano drug delivery system loaded with cyclosporine according to any one of claims 1 to 3, characterized in that: The particle size of the nano drug delivery system is 5-100 nm.
5. The method for preparing the cyclosporine-loaded ophthalmic nano drug delivery system according to any one of claims 1 to 4, characterized in that: The preparation method comprises: mixing and dissolving cyclosporine and an aqueous solution of an amphiphilic polymer to obtain the cyclosporine-loaded ophthalmic nano drug delivery system.
6. Use of the cyclosporine-loaded ophthalmic nanodrug delivery system according to any one of claims 1 to 4 in the preparation of an ophthalmic cyclosporine preparation.
7. A cyclosporine eye drop, characterized in that: The raw materials for preparing the cyclosporine eye drops include the ophthalmic nano drug delivery system loaded with cyclosporine according to any one of claims 1 to 4.
8. The cyclosporine eye drops according to claim 7, characterized in that The raw materials for preparing the cyclosporine eye drops also include any one of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative, or a combination of at least two of them.
9. The cyclosporine eye drops according to claim 7 or 8, characterized in that: The mass percentage of cyclosporine in the cyclosporine eye drops is not less than 0.05%.
10. The method for preparing cyclosporine eye drops according to any one of claims 7 to 9, characterized in that: The preparation method comprises: Any one or a combination of at least two of an osmotic pressure regulator, a pH regulator, a thickener, and a preservative are mixed with cyclosporine and an amphiphilic polymer and dissolved in water, and water is added to adjust the total volume so that the cyclosporine reaches the target concentration.
Citation Information
Patent Citations
Topical drug delivery systems for ophthalmic use
CN102458370A
Blank mixed micelle, and preparation method and applications thereof
CN108420793A
Ultrasonically-enhanced continuous and large-scale production method for nano-formulations
WO2023109836A1
Cited By
Ophthalmic cyclosporine nano-micelle drug, preparation method therefor, and use thereof
WO2025108351A1
